Journal Scans
Neoadjuvant Capecitabine and Oxaliplatin Before Chemoradiotherapy and Total Mesorectal Excision in MRI-Defined Poor-Risk Rectal Cancer: A Phase 2 Trial
Neoadjuvant Capecitabine and Oxaliplatin in Poor-Risk Rectal Cancer
YJ Chua, Y Barbachano, D Cunningham , JR Oates, G Brown, A Wotherspoon, D Tait, A Massey, NC Tebbutt, I Chau
20100026
2010 Jan 26
Lancet Oncol
Neoadjuvant Capecitabine and Oxaliplatin Before Chemoradiotherapy and Total Mesorectal Excision in MRI-Defined Poor-Risk Rectal Cancer: A Phase 2 Trial
Lancet Oncol. 2010 Jan 26; Epub ahead of print, YJ Chua, Y Barbachano, D Cunningham , JR Oates, G Brown, A Wotherspoon, D Tait, A Massey, NC Tebbutt, I Chau
TAKE-HOME MESSAGE
Abstract
Abstract
Background: Patients with poor-risk rectal cancer defined by MRI can be at high risk of disease recurrence despite standard chemoradiotherapy and optimum surgery. We aimed to assess the safety and long-term efficacy of neoadjuvant chemotherapy with capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision, a treatment strategy developed to enhance the outcome of this population. Methods: Between November, 2001, and August, 2005, we enrolled eligible patients with poor-risk...
